2024
Ending Weight Stigma to Advance Health Equity
Pearl R, Donze L, Rosas L, Agurs-Collins T, Baskin M, Breland J, Byker Shanks C, Cooksey Stowers K, Johnson S, Lee B, Martin M, Mujuru P, Odoms-Young A, Panza E, Pronk N, Calicutt K, Nadglowski J, Nece P, Tedder M, Chow L, Krishnamurti H, Jay M, Xi D, Jastreboff A, Stanford F. Ending Weight Stigma to Advance Health Equity. American Journal Of Preventive Medicine 2024 PMID: 38945180, DOI: 10.1016/j.amepre.2024.06.021.Peer-Reviewed Original ResearchEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, Bozkurt B, Budoff M, Butler J, Cherney D, DeFronzo R, Del Prato S, Eckel R, Filippatos G, Fonarow G, Fonseca V, Garvey W, Giorgino F, Grant P, Green J, Greene S, Groop P, Grunberger G, Jastreboff A, Jellinger P, Khunti K, Klein S, Kosiborod M, Kushner P, Leiter L, Lepor N, Mantzoros C, Mathieu C, Mende C, Michos E, Morales J, Plutzky J, Pratley R, Ray K, Rossing P, Sattar N, Schwarz P, Standl E, Steg P, Tokgözoğlu L, Tuomilehto J, Umpierrez G, Valensi P, Weir M, Wilding J, Wright E. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism 2024, 155931. PMID: 38852020, DOI: 10.1016/j.metabol.2024.155931.Peer-Reviewed Original ResearchChronic kidney diseaseAtherosclerotic cardiovascular diseaseHeart failureMetabolic diseasesCardiorenal risk factorsEssentials of managementPractice recommendationsType 2 diabetesImprove patient outcomesVolunteer task forcePrimary care physiciansMetabolic comorbiditiesMultispecialty consensusOutcome trialsManagement of personsKidney diseaseLiver diseasePathophysiological pathwaysPulmonary diseaseRisk factorsSteatotic liver diseaseManagement of diabetesCardiovascular diseasePatient outcomesCare physiciansOnce-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial
Jastreboff A, Kaplan L, Frias J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M, Blüher M. Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial. Diabetologie Und Stoffwechsel 2024, 19: s77-s78. DOI: 10.1055/s-0044-1785389.Peer-Reviewed Original ResearchRetatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study
Coskun T, Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Hartman M, Haupt A, Milicevic Z, Seufert J. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study. Diabetologie Und Stoffwechsel 2024, 19: s72-s73. DOI: 10.1055/s-0044-1785379.Peer-Reviewed Original Research
2023
Reflecting on a Year at the Helm of Diabetes Care.
Kahn S, Anderson C, Buse J, Selvin E, Angell S, Aroda V, Cheng A, Danne T, Echouffo-Tcheugui J, Fitzpatrick S, Gadgil M, Gastaldelli A, Gloyn A, Green J, Jastreboff A, Kanaya A, Kandula N, Kovesdy C, Laiteerapong N, Nadeau K, Pettus J, Pop-Busui R, Posey J, Powe C, Rebholz C, Rickels M, Sattar N, Shaw J, Sims E, Utzschneider K, Vella A, Zhang C. Reflecting on a Year at the Helm of Diabetes Care. Diabetes Care 2023, 47: 4-6. PMID: 38117988, DOI: 10.2337/dci23-0089.Peer-Reviewed Original ResearchEligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original ResearchTriple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
Jastreboff A, Kaplan L, Hartman M. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. New England Journal Of Medicine 2023, 389: 1629-1630. PMID: 37888927, DOI: 10.1056/nejmc2310645.Peer-Reviewed Original ResearchNaltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionReducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targetsTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeksAssociation between specific types of parent stressors and fast-food consumption among parents and children
Bautista T, Fogelman N, Lartigue S, Silverman W, Jastreboff A, Sinha R. Association between specific types of parent stressors and fast-food consumption among parents and children. Eating Behaviors 2023, 49: 101724. PMID: 37054487, PMCID: PMC10247538, DOI: 10.1016/j.eatbeh.2023.101724.Peer-Reviewed Original ResearchConceptsHousehold chaosParent stressorsYoung childrenOnly significant predictorSignificant predictorsFast food consumptionStress interventionsSeparate regression modelsParentsSpecific typesYear oldsChildrenStressorsFast food intakeChildren's fast food consumptionPredictorsFinal modelHealthy foodsOldsBehaviorStressInterventionTurnBody mass indexFindingsChampioning the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF)
Weghuber D, Khandpur N, Boyland E, Mazur A, Frelut M, Forslund A, Vlachopapadopoulou E, Erhardt É, Vania A, Molnar D, Ring‐Dimitriou S, Caroli M, Mooney V, Forhan M, Ramos‐Salas X, Pulungan A, Holms J, O'Malley G, Baker J, Jastreboff A, Baur L, Thivel D. Championing the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF). Pediatric Obesity 2023, 18: e13024. PMID: 37002830, DOI: 10.1111/ijpo.13024.Peer-Reviewed Original ResearchTirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis
Aronne L, Jastreboff A, Le Roux C, Malik R, Ahmad N, Liu B, Bunck M, Zhang S, Stefanski A, Lautenbach A. Tirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis. Diabetologie Und Stoffwechsel 2023, 18: s42-s43. DOI: 10.1055/s-0043-1767938.Peer-Reviewed Original ResearchNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgentsWhen Weight Impacts Health
Aronne L, Bramblette S, Ingelfinger J, Jastreboff A, Machineni S, Massie N, Rosen C. When Weight Impacts Health. New England Journal Of Medicine 2023, 388: e2. PMID: 36630621, DOI: 10.1056/nejmp2215794.Peer-Reviewed Original Research
2022
"The Times They Are A-Changin'" at Diabetes Care.
Kahn S, Anderson C, Buse J, Selvin E, Angell S, Aroda V, Castle J, Cheng A, Danne T, Echouffo-Tcheugui J, Florez J, Gadgil M, Gastaldelli A, Green J, Jastreboff A, Kanaya A, Kandula N, Kovesdy C, Laiteerapong N, Nadeau K, Pop-Busui R, Powe C, Rebholz C, Rickels M, Sattar N, Shaw J, Sims E, Utzschneider K, Vella A, Zhang C. "The Times They Are A-Changin'" at Diabetes Care. Diabetes Care 2022, 46: 3-5. PMID: 36548704, DOI: 10.2337/dci22-0045.Peer-Reviewed Original ResearchWeight and Health — Pathophysiology and Therapies
Aronne L, Bramblette S, Huett-Garcia A, Ingelfinger J, Jastreboff A, Machineni S, Massie N, Rosen C. Weight and Health — Pathophysiology and Therapies. New England Journal Of Medicine 2022, 387: e62. PMID: 36516089, DOI: 10.1056/nejmp2214423.Peer-Reviewed Original Research